These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
292 related articles for article (PubMed ID: 28413097)
41. Preclinical predictors that the orthosteric mGlu2/3 receptor antagonist LY3020371 will not engender ketamine-associated neurotoxic, motor, cognitive, subjective, or abuse-liability-related effects. Witkin JM; Monn JA; Li J; Johnson B; McKinzie DL; Wang XS; Heinz BA; Li R; Ornstein PL; Smith SC; Mitch CH; Calligaro DO; Swanson S; Allen D; Phillips K; Gilmour G Pharmacol Biochem Behav; 2017 Apr; 155():43-55. PubMed ID: 28285123 [TBL] [Abstract][Full Text] [Related]
42. Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity. Gerhard DM; Wohleb ES; Duman RS Drug Discov Today; 2016 Mar; 21(3):454-64. PubMed ID: 26854424 [TBL] [Abstract][Full Text] [Related]
43. Is the mGlu5 receptor a possible target for new antidepressant drugs? Pałucha-Poniewiera A; Wierońska JM; Brański P; Burnat G; Chruścicka B; Pilc A Pharmacol Rep; 2013; 65(6):1506-11. PubMed ID: 24552998 [TBL] [Abstract][Full Text] [Related]
46. The role of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in depression: central mediators of pathophysiology and antidepressant activity? Freudenberg F; Celikel T; Reif A Neurosci Biobehav Rev; 2015 May; 52():193-206. PubMed ID: 25783220 [TBL] [Abstract][Full Text] [Related]
47. The mGlu5 receptor antagonist MPEP activates specific stress-related brain regions and lacks neurotoxic effects of the NMDA receptor antagonist MK-801: significance for the use as anxiolytic/antidepressant drug. Inta D; Filipovic D; Lima-Ojeda JM; Dormann C; Pfeiffer N; Gasparini F; Gass P Neuropharmacology; 2012 Apr; 62(5-6):2034-9. PubMed ID: 22261382 [TBL] [Abstract][Full Text] [Related]
55. Activation of the mTOR signaling pathway in the antidepressant-like activity of the mGlu5 antagonist MTEP and the mGlu7 agonist AMN082 in the FST in rats. Pałucha-Poniewiera A; Szewczyk B; Pilc A Neuropharmacology; 2014 Jul; 82():59-68. PubMed ID: 24631968 [TBL] [Abstract][Full Text] [Related]
56. The involvement of glutamate in the pathophysiology of depression. Palucha A; Pilc A Drug News Perspect; 2005 May; 18(4):262-8. PubMed ID: 16034483 [TBL] [Abstract][Full Text] [Related]
57. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. Galici R; Echemendia NG; Rodriguez AL; Conn PJ J Pharmacol Exp Ther; 2005 Dec; 315(3):1181-7. PubMed ID: 16123306 [TBL] [Abstract][Full Text] [Related]
58. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). Fell MJ; Svensson KA; Johnson BG; Schoepp DD J Pharmacol Exp Ther; 2008 Jul; 326(1):209-17. PubMed ID: 18424625 [TBL] [Abstract][Full Text] [Related]
59. Discovery of (1S,2R,3S,4S,5R,6R)-2-Amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Hydrochloride (LY3020371·HCl): A Potent, Metabotropic Glutamate 2/3 Receptor Antagonist with Antidepressant-Like Activity. Chappell MD; Li R; Smith SC; Dressman BA; Tromiczak EG; Tripp AE; Blanco MJ; Vetman T; Quimby SJ; Matt J; Britton TC; Fivush AM; Schkeryantz JM; Mayhugh D; Erickson JA; Bures MG; Jaramillo C; Carpintero M; Diego JE; Barberis M; Garcia-Cerrada S; Soriano JF; Antonysamy S; Atwell S; MacEwan I; Condon B; Sougias C; Wang J; Zhang A; Conners K; Groshong C; Wasserman SR; Koss JW; Witkin JM; Li X; Overshiner C; Wafford KA; Seidel W; Wang XS; Heinz BA; Swanson S; Catlow JT; Bedwell DW; Monn JA; Mitch CH; Ornstein PL J Med Chem; 2016 Dec; 59(24):10974-10993. PubMed ID: 28002967 [TBL] [Abstract][Full Text] [Related]
60. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. Monn JA; Valli MJ; Massey SM; Hansen MM; Kress TJ; Wepsiec JP; Harkness AR; Grutsch JL; Wright RA; Johnson BG; Andis SL; Kingston A; Tomlinson R; Lewis R; Griffey KR; Tizzano JP; Schoepp DD J Med Chem; 1999 Mar; 42(6):1027-40. PubMed ID: 10090786 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]